Type i interferons mediate pancreatic toxicities of PERK inhibition

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 50, 2015, Pages 15420-15425

  Yu, Qiujing ^a   Zhao, Bin ^a   Gui, Jun ^a   Katlinski, Kanstantsin V ^a   Brice, Angela ^a   Gao, Yan ^b   Li, Changhong ^c   Kushner, Jake A ^d   Koumenis, Constantinos ^e   Alan Diehl, J ^b   Fuchs, Serge Y ^a  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d TEXAS CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Diabetes; Interferon; Pancreas; PERK; Wolcott Rallison syndrome

Indexed keywords

GLUCOSE REGULATED PROTEIN 94; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 7; MESSENGER RNA; PANCREATIC ENDOPLASMIC RETICULUM KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; TYPE 1 INTERFERON RECEPTOR; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; CASPASE 3; IFNAR1 PROTEIN, MOUSE; INTERFERON; PERK KINASE; PROTEIN KINASE R; AMYLASE; BLOCKING ANTIBODY; GLUCOSE; INSULIN; NEUTRALIZING ANTIBODY; PHOSPHOTRANSFERASE INHIBITOR; TAMOXIFEN;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CELL CULTURE; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME INHIBITION; FEMALE; GLUCOSE TOLERANCE TEST; HELA CELL LINE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS INJURY; PANCREAS ISLET CELL; PANCREATIC TISSUE; PANCREATIC TOXICITY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DOWN REGULATION; DRUG EFFECTS; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PANCREAS; PANCREAS ISLET; PATHOLOGY; UNFOLDED PROTEIN RESPONSE; UPREGULATION; ACINAR CELL; AMYLASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN RELEASE; PANCREAS DISEASE; TOXICITY;

ANIMALS; APOPTOSIS; CASPASE 3; DIABETES MELLITUS, EXPERIMENTAL; DOWN-REGULATION; EIF-2 KINASE; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; INTERFERON TYPE I; ISLETS OF LANGERHANS; MICE; PANCREAS; PROTEIN KINASE INHIBITORS; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE; UP-REGULATION;

EID: 84950111776     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1516362112     Document Type: Article

References (64)

1. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411(6835):375-379.
2. Diehl JA, Fuchs SY, Koumenis C (2011) The cell biology of the unfolded protein response. Gastroenterology 141:38-41.
3. Bobrovnikova-Marjon E, et al. (2010) PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene 29(27):3881-3895.
4. Koumenis C (2006) ER stress, hypoxia tolerance and tumor progression. Curr Mol Med 6(1):55-69.
5. Fels DR, Koumenis C (2006) The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol Ther 5(7):723-728.
6. Bi M, et al. (2005) ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J 24(19):3470-3481.
7. Wang Y, et al. (2012) The unfolded protein response induces the angiogenic switch in human tumor cells through the PERK/ATF4 pathway. Cancer Res 72(20):5396-5406.
8. Jamison S, Lin Y, Lin W (2015) Pancreatic endoplasmic reticulum kinase activation promotes medulloblastoma cell migration and invasion through induction of vascular endothelial growth factor A. PLoS One 10(3):e0120252.
9. Karali E, et al. (2014) VEGF Signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress. Mol Cell 54(4):559-572.
10. Wouters BG, et al. (2005) Control of the hypoxic response through regulation of mRNA translation. Semin Cell Dev Biol 16(4-5):487-501.
11. Blais JD, et al. (2006) Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. Mol Cell Biol 26(24): 9517-9532.
12. Blais JD, et al. (2004) Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol 24(17):7469-7482.
13. Martins I, et al. (2011) Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30(10):1147-1158.
14. Zitvogel L, et al. (2010) Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010;16(12):3100-3104.
15. Hou X, et al. (2015) PERK silence inhibits glioma cell growth under low glucose stress by blockage of p-AKT and subsequent HK2's mitochondria translocation. Sci Rep 5:9065.
16. Ma XH, et al. (2014) Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest 124(3):1406-1417.
17. Dey S, Tameire F, Koumenis C (2013) PERK-ing up autophagy during MYC-induced tumorigenesis. Autophagy 9(4):612-614.
18. Hart LS, et al. (2012) ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J Clin Invest 122(12):4621-4634.
19. Chitnis NS, et al. (2012) miR-211 is a prosurvival microRNA that regulates chop expression in a PERK-dependent manner. Mol Cell 48(3):353-364.
20. Blais J, Bell JC (2006) Novel therapeutic target: the PERKs of inhibiting the integrated stress response. Cell Cycle 5(24):2874-2877.
21. Maly DJ, Papa FR (2014) Druggable sensors of the unfolded protein response. Nat Chem Biol 10(11):892-901.
22. Atkins C, et al. (2013) Characterization of a novel PERK kinase inhibitor with antitu-mor and antiangiogenic activity. Cancer Res 73(6):1993-2002.
23. Axten JM, et al. (2012) Discovery of 7-methyl-5-(1-[3-(trifluoromethyl)phenyl]acetyl-2, 3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2, 3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum ki-nase (PERK). J Med Chem 55(16):7193-7207.
24. Axten JM, et al. (2013) Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development. ACS Med Chem Lett 4(10):964-968.
25. Moreno JA, et al. (2013) Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med 5(206):206ra138.
26. Halliday M, et al. (2015) Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. Cell Death Dis 6:e1672.
27. Harding HP, Zyryanova AF, Ron D (2012) Uncoupling proteostasis and development in vitro with a small molecule inhibitor of the pancreatic endoplasmic reticulum ki-nase, PERK. J Biol Chem 287(53):44338-44344.
28. Julier C, Nicolino M (2010) Wolcott-Rallison syndrome. Orphanet J Rare Dis 5:29.
29. Kaufman RJ, Back SH, Song B, Han J, Hassler J (2010) The unfolded protein response is required to maintain the integrity of the endoplasmic reticulum, prevent oxidative stress and preserve differentiation in β-cells. Diabetes Obes Metab 12(Suppl 2): 99-107.
30. Cavener DR, Gupta S, McGrath BC (2010) PERK in beta cell biology and insulin biogenesis. Trends Endocrinol Metab 21(12):714-721.
31. Harding HP, Ron D (2002) Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 51(Suppl 3):S455-S461.
32. Gao Y, et al. (2012) PERK is required in the adult pancreas and is essential for maintenance of glucose homeostasis. Mol Cell Biol 32(24):5129-5139.
33. Gupta S, McGrath B, Cavener DR (2009) PERK regulates the proliferation and development of insulin-secreting beta-cell tumors in the endocrine pancreas of mice. PLoS One 4(11):e8008.
34. Feng D, Wei J, Gupta S, McGrath BC, Cavener DR (2009) Acute ablation of PERK results in ER dysfunctions followed by reduced insulin secretion and cell proliferation. BMC Cell Biol 10:61.
35. Iida K, Li Y, McGrath BC, Frank A, Cavener DR (2007) PERK eIF2 alpha kinase is required to regulate the viability of the exocrine pancreas in mice. BMC Cell Biol 8:38.
36. Zhang W, et al. (2006) PERK EIF2AK3 control of pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis. Cell Metab 4(6): 491-497.
37. Zhang P, et al. (2002) The PERK eukaryotic initiation factor 2 alpha kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. Mol Cell Biol 22(11):3864-3874.
38. Harding HP, et al. (2001) Diabetes mellitus and exocrine pancreatic dysfunction in perk-/-mice reveals a role for translational control in secretory cell survival. Mol Cell 7(6):1153-1163.
39. Bhattacharya S, et al. (2013) Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses. Oncogene 32(36):4214-4221.
40. Bhattacharya S, et al. (2011) Role of p38 protein kinase in the ligand-independent ubiquitination and down-regulation of the IFNAR1 chain of type I interferon receptor. J Biol Chem 286(25):22069-22076.
41. Bhattacharya S, et al. (2010) Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor. J Biol Chem 285(4):2318-2325.
42. Liu J, et al. (2009) Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host Microbe 5(1):72-83.
43. Platanias LC (2005) Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 5(5):375-386.
44. Trinchieri G (2010) Type I interferon: friend or foe? J Exp Med 207(10):2053-2063.
45. Huang X, et al. (1995) Interferon expression in the pancreases of patients with type I diabetes. Diabetes 44(6):658-664.
46. Foulis AK, Farquharson MA, Meager A (1987) Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 2(8573):1423-1427.
47. Tannir NM, Talpaz M, Ghazal H, Proothi S, Kantarjian HM (2000) Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia. Leuk Lymphoma 39(5-6):647-650.
48. Eland IA, van Puijenbroek EP, Sturkenboom MJ, Wilson JH, Stricker BH (1999) Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. Am J Gastroenterol 94(9):2417-2422.
49. Morris DJ (1994) Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf 10(4):281-291.
50. Guerci AP, et al. (1994) Onset of insulin-dependent diabetes mellitus after interferon-alfa therapy for hairy cell leukaemia. Lancet 343(8906):1167-1168.
51. Fabris P, et al. (2003) Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 18(6):549-558.
52. Stewart TA, et al. (1993) Induction of type I diabetes by interferon-alpha in transgenic mice. Science 260(5116):1942-1946.
53. Li Q, McDevitt HO (2011) The role of interferon alpha in initiation of type I diabetes in the NOD mouse. Clin Immunol 140(1):3-7.
54. Li Q, et al. (2008) Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA 105(34):12439-12444.
55. Schreiber G, Piehler J (2015) The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol 36(3):139-149.
56. Piehler J, Thomas C, Garcia KC, Schreiber G (2012) Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol Rev 250(1):317-334.
57. Bhattacharya S, et al. (2014) Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury. EMBO Mol Med 6(3):384-397.
58. Liu J, et al. (2008) Ligand-independent pathway that controls stability of interferon alpha receptor. Biochem Biophys Res Commun 367(2):388-393.
59. Liu J, et al. (2009) Mammalian casein kinase 1alpha and its leishmanial ortholog regulate stability of IFNAR1 and type I interferon signaling. Mol Cell Biol 29(24): 6401-6412.
60. Holland AM, Góñez LJ, Naselli G, Macdonald RJ, Harrison LC (2005) Conditional expression demonstrates the role of the homeodomain transcription factor Pdx1 in maintenance and regeneration of beta-cells in the adult pancreas. Diabetes 54(9): 2586-2595.
61. Higgs BW, et al. (2014) A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 73(1):256-262.
62. McBride JM, et al. (2012) Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 64(11):3666-3676.
63. Sheehan KC, et al. (2006) Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic trans-fection. J Interferon Cytokine Res 2006;26:804-819.
64. Schindelin J, et al. (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9(7):676-682.